Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Talal Hilal

Lymphoma · Mayo Clinic College of Medicine

View

Dr. Midhun Malla

GI Oncology · UAB

View

Dr. Saad Usmani

Myeloma · MSK

View

Dr. Kamal Menghrajani

Leukemia · MGH

View

Dr. Hope Rugo

Breast Oncology · City of Hope

View

Dr. Gideon Dosunmu

GI Oncology · Emory Hospital Midtown

View

Dr. Pavlos Msaouel

GU Oncology · MD Anderson Cancer Center

View

Dr. Virginia Borges

Breast Oncology · CU Anschutz Medical Campus

View

Dr. Naval Daver

Leukemia · MD Anderson Cancer Center

View

Dr. William Gradishar

Breast Oncology · NU

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    PNDr. Prakash Neupane

    Dr. Prakash Neupane

    Hematology & Oncology · Head & Neck Oncology
    The University of Kansas Health System
    prakashn

    Research

    Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study.

    2025

    Via European Journal of Cancer

    Research

    Comparison of the effectiveness of oral morphine versus oral tramadol on early pain control in opioid-naive patients with moderate cancer pain.

    2025

    Via Ecancermedicalscience

    Research

    Tarlatamab-induced immune-related adverse events: Real-world pharmacovigilance study using the FAERS database.

    2025

    Via European Journal of Cancer

    Research

    Safety, Efficacy, and Central Nervous System Control in Patients with High Baseline Risk Factors Treated with Tarlatamab for SCLC or Extrapulmonary Small Cell Carcinoma.

    2025

    Via JTO Clinical and Research Reports

    Research

    Response to letter Re: Tarlatamab-induced immune-related adverse events: Real-world pharmacovigilance study using the FAERS database.

    2025

    Via European Journal of Cancer

    Research

    Impact of Adjuvant Radiotherapy Setting on Quality-of-Life in Head and Neck Squamous Cell Carcinoma.

    2024

    Via The Laryngoscope

    Research

    Final outcomes analysis of the cell product SQZ-PBMC-HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration.

    2024

    Via Molecular Carcinogenesis

    Research

    Tarlatamab Rechallenge After Grade 3 Cytokine Release Syndrome Leading to Tumor Regression in Two Weeks and Reopening of a Collapsed Lung: A Case Report.

    2024

    Via Clinical Lung Cancer

    Research

    Prognostic Implications of Skin Invasion in Locally Advanced Oral Cavity Squamous Cell Carcinoma.

    2023

    Via Otolaryngology--Head and Neck Surgery

    Research

    Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors.

    2023

    Via Investigational New Drugs

    Research

    Lung Cancer in Nepal.

    2022

    Via Journal of Thoracic Oncology

    Research

    Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score.

    2022

    Via Journal of Clinical Oncology

    Research

    Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.

    2022

    Via Oral Oncology

    Research

    Sarcopenia and Treatment Toxicity in Older Adults Undergoing Chemoradiation for Head and Neck Cancer: Identifying Factors to Predict Frailty.

    2022

    Via Cancers

    Research

    Treatment Tolerance of Cetuximab versus Alternative Chemotherapy Agents in Non-Cisplatin Candidates with Head and Neck Cancer Receiving Concurrent Chemoradiotherapy.

    2022

    Via Chemotherapy